Milestone Pharmaceuticals Inc. (MIST)

Milestone Pharmaceuticals Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	25.31	13.76	7.64	114.14	72.31
Short-Term Investments	44.38	52.24	56.95	-	70
Cash & Short-Term Investments	69.7	66	64.59	114.14	142.31
Cash Growth	5.59%	2.20%	-43.42%	-19.79%	18.77%
Other Receivables	1.72	1.45	1.21	0.48	0.95
Receivables	1.72	1.45	1.21	0.48	0.95
Prepaid Expenses	1.84	3.18	6.01	4.3	5.43
Other Current Assets	0.67	2.4	-	-	-
Total Current Assets	73.93	73.03	71.8	118.92	148.69
Property, Plant & Equipment	1.57	2.19	2.68	0.93	1.29
Total Assets	75.5	75.23	74.48	119.85	149.97
Accounts Payable	1.93	3.98	2.26	4.38	4.64
Accrued Expenses	5.62	2.7	3.38	2.17	1.27
Current Portion of Leases	0.57	0.55	0.5	0.22	0.25
Total Current Liabilities	8.13	7.23	6.14	6.78	6.16
Long-Term Debt	53.35	49.77	-	-	-
Long-Term Leases	0.87	1.46	2	0.47	0.7
Total Liabilities	62.35	58.46	8.14	7.25	6.86
Common Stock	288.05	260.5	273.9	251.9	251.68
Additional Paid-In Capital	39.57	33.83	24.44	15.71	8.53
Retained Earnings	-367.55	-326.03	-266.34	-207.95	-163.47
Comprehensive Income & Other	53.08	48.46	34.35	52.94	46.37
Total Common Equity	13.15	16.77	66.35	112.6	143.12
Shareholders' Equity	13.15	16.77	66.35	112.6	143.12
Total Liabilities & Equity	75.5	75.23	74.48	119.85	149.97
Total Debt	54.8	51.78	2.49	0.7	0.94
Net Cash (Debt)	14.9	14.23	62.09	113.44	141.37
Net Cash Growth	4.71%	-77.09%	-45.26%	-19.75%	18.50%
Net Cash Per Share	0.24	0.33	1.46	2.71	4.82
Filing Date Shares Outstanding	66.26	43.06	42.8	42.23	41.25
Total Common Shares Outstanding	66.26	43.06	42.8	42.23	41.25
Working Capital	65.8	65.81	65.66	112.15	142.53
Book Value Per Share	0.20	0.39	1.55	2.67	3.47
Tangible Book Value	13.15	16.77	66.35	112.6	143.12
Tangible Book Value Per Share	0.20	0.39	1.55	2.67	3.47
Machinery	0.4	0.38	0.28	0.43	0.43
Leasehold Improvements	0.09	0.09	0.1	0.03	0.03

Updated Mar 13, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q